Developer docs
API playgroundTry for free, no card

Search company profiles

Bio-Gate

Full company profile

uuid000gpfj

Namestring
Bio-Gate
Legal namestring
Bio-Gate AG
Websiteurl
bio-gate.de
Company typeenum
Public
Founded yearint
2000
Descriptiontext

Bio-Gate AG is a Nuremberg-based German health technology company founded in 2000, listed on the German stock exchange (ISIN DE000BGAG981), that develops and commercializes silver-based antimicrobial and antiviral technologies for use across medical, cosmetic, veterinary, and industrial applications. Its two proprietary platforms are MicroSilver BG™, a highly pure, microporous elemental silver additive that can be incorporated into materials and formulations, and HyProtect™, an ultrathin (<200 nm) plasma coating combining pure silver and polysiloxane designed to protect medical implant surfaces against bacterial colonization, including multi-resistant organisms. Manufacturing is conducted in Bremen under DIN EN ISO 13485:2016 and DIN EN ISO 9001:2015, and the MicroSilver BG ingredient carries ECOCERT, COSMOS, and NPA natural product certifications.

The company monetizes through three channels: (1) B2B technology licensing and coating services to medical device manufacturers (notably orthopedic and trauma implant partners, with an FDA-track trauma LOI and a CE-track hip revision RCT of 200+ patients expected to read out in 2027); (2) sale of proprietary consumer products spanning derma cosmetics, wound care, and animal care (including the Silver Honey® line with W.F. Young in North America and horse care SKUs); and (3) accredited microbiological laboratory services through its wholly owned subsidiary QualityLabs BT GmbH, whose CERTIKA methods are recognized by European notified bodies and stored as FDA master files. A veterinary-exclusive joint venture, VetInnovations GmbH, is co-owned with LABOKLIN.

Distribution is hybrid: direct enterprise field sales to global medical device companies combined with multi-channel retail and e-commerce distribution (PetSmart, Petco, Walmart, Tractor Supply, Amazon, Chewy) for animal care, plus pharmacy and drugstore channels for derma cosmetics. The company operates representative offices in Bolton, Ontario (RFH BioTek Inc.) and Guangzhou (WunderTek) to support North American and Chinese business development. FY2025 revenue was 7.4M EUR (+4.9% YoY), with the veterinary segment up 48% and EBITDA loss narrowing 31.3% to -896 TEUR as the company approaches operational break-even.

Short descriptiontext

Bio-Gate AG is a German health technology company that develops silver-based antimicrobial technologies (MicroSilver BG™ additive and HyProtect™ plasma coating) for medical implants, wound care, derma cosmetics, veterinary, and industrial hygiene applications, and licenses them to medical device and consumer product partners globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNürnberg, Germany
HQ citystring
Nürnberg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial silver technology, medical implant coatings, antimicrobial wound care, veterinary dermatology products, industrial hygiene additives
Industry3 codes
PRIMARYHLAMAEAE
Antimicrobials & Anti-infectives
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAGADAE
Microbiology & Sterility Assurance (Bioburden/Endotoxin/Sterility)
SECONDARYAFAJAFAF
Natural Antimicrobials & Clean-Label Preservatives (Plant Extracts, Essential Oils, Fermented Extracts)
Agriculture & Food Production/Food Ingredients & Additives/Preservatives & Antimicrobials (Organic Acids, Nitrates, Cultured Dextrose)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Commercial Physical & Biological Research8731
Product category
Antimicrobial medical technologies and infection-prevention products
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing and Coating Services
TypeLicensing Royalties
Description

Licensing of proprietary antimicrobial technologies (MicroSilver BG™ and HyProtect™) to medical device manufacturers and consumer product companies. Revenue generated through technology licensing fees, development partnerships, and coating service contracts for implants and medical devices.

bio-gate.de
2Proprietary Consumer Products
TypeHardware Sales
Description

Sale of finished derma cosmetics, wound care, and veterinary care products. Includes CBD-based skincare products, MicroSilver BG™ skincare lines, and animal care products distributed through retail chains, pharmacies, and veterinary channels.

bio-gate.de
3Laboratory Testing Services
TypeProfessional Services
Description

Microbiological testing services through subsidiary QualityLabs BT GmbH, providing antimicrobial and anti-adhesive property testing using methods including CERTIKA, QualiScreen, ISO 22196/JIS Z 2801, ISO 20743/JIS L 1902, ASTM E 2180, ASTM E 2149.

bio-gate.de
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1HyProtect
Description

Ultrathin plasma coating technology that protects medical implant surfaces against bacterial colonisation using polysiloxane and silver combination.

bio-gate.de
+2 more records
Core offering1 text field

Bio-Gate AG commercializes proprietary silver-based antimicrobial and antiviral technologies — MicroSilver BG™ (a microporous elemental silver additive) and HyProtect™ (an ultrathin plasma silver-polysiloxane coating) — applied to medical devices, wound care, derma cosmetics, veterinary products, and industrial materials. The company licenses its technologies to medical device manufacturers, coats implants and other products, sells branded consumer and animal care products, and offers accredited microbiological testing through its QualityLabs BT GmbH subsidiary.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Infection rate <1% with HyProtect™ coated veterinary implants vs typical 15% infection rate
+5 more records
Product overview1 text field

Bio-Gate AG is a health technology company specializing in antimicrobial and antiviral technologies. The core offerings consist of two proprietary technologies: MicroSilver BG™ (a highly pure elemental microporous silver additive) and HyProtect™ (an ultrathin plasma coating combining silver and polysiloxane). These technologies are applied across four main business segments: Medical Technology (wound dressings, implant coatings, dental materials, bone cement, catheters), Derma Cosmetics (skincare for acne, neurodermatitis, rosacea, diabetic foot), Veterinary (animal care products for skin/ear/wound care and implant coatings), and Industry+Hygiene (textiles, sprays, polymers, paints, foams). The company also operates QualityLabs BT GmbH for microbiological testing and VetInnovations GmbH as a joint venture for veterinary dermatology products.

Product and service14 records
1MicroSilver BG™
CategoryAntimicrobial silver additive / technology ingredient
Description

MicroSilver BG™ is a highly pure, microporous elemental silver additive with antimicrobial and antiviral properties. It is supplied as an ingredient or additive that can be incorporated into materials and formulations for skincare, oral care, wound care, textiles, polymers, paints, foams, and medical implants. Certified natural by ECOCERT, COSMOS, and NPA.

2HyProtect™ Coating Technology
3HyProtect™-coated Implants
4Wound Dressings with MicroSilver BG™
5Dental Materials with MicroSilver BG™
6Bone Cement with MicroSilver BG™
7Derma Cosmetic Products with MicroSilver BG™
8CBD Muscle Gel
9Silver Honey® Rapid Ear Care Line
10Veterinary Skin, Ear, and Wound Care Products
11Horse Care Products (Balm, Spray, Strahlgel)
12MicroSilver BG™-Tec Industrial Additives (Textiles, Polymers, Paints, PU Foams, Sprays)
13QualityLabs BT GmbH Accredited Microbiological Testing Services
14VetInnovations GmbH Veterinary Dermatology Products
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-07-31
Description

Letter of Intent signed for use of Bio-Gate's HyProtect™ coating process for trauma implants following FDA approval. Represents significant growth potential in human medicine market.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-02-01
Description

US-based animal health specialist distributing Silver Honey® Rapid Ear Care line products developed and manufactured by Bio-Gate. Products combine MicroSilver BG™ and Manuka honey for antibiotic-free ear infection treatment in pets.

3Dermatest GmbH
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Independent dermatological testing institute in Münster conducting clinical studies on Bio-Gate products. Awarded 'sehr gut' (very good) rating to CBD muscle gel in 2025 study.

bio-gate.de
Strategic tierCoreTypeOthersAnnounced on2004-01-01
Description

Accredited microbiological testing laboratory spun off from Bio-Gate in 2004. Provides antimicrobial testing services including CERTIKA test methods recognized by European notified bodies and FDA. Generates testing services revenue for the group.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint venture between LABOKLIN GmbH & Co. KG and Bio-Gate AG developing and selling dermatological care and wound care products for small animals. Products based on MicroSilver BG™ technology. Exclusively serves veterinarians.

6LABOKLIN GmbH & Co. KG
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Veterinary laboratory and diagnostics company co-founding VetInnovations joint venture with Bio-Gate for veterinary dermatology products.

bio-gate.de
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

North American representative office in Bolton, Ontario representing Bio-Gate for veterinary products and business development. Contact: Karl F. Richter.

8Guangzhou WunderTek Biotechnology Co. Ltd
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Chinese representative office in Guangzhou providing local business development and customer support for Chinese market.

bio-gate.de
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large German medical device and pharmaceutical company with broad portfolio including antiseptics, wound care, and orthopedic implants. Overlaps with Bio-Gate's medical technology segment as a broader incumbent competitor and potential customer for HyProtect™ coating.

TypeDirect peer
Description

Global wound care specialist (Mepilex, etc.) with antimicrobial dressings. Comparable to Bio-Gate's wound care segment using MicroSilver BG™ in wound dressings, though at much larger scale.

TypeBroad incumbent
Description

Global medical technology company with wound care, orthopedics, and sports medicine franchises. Comparable across both Bio-Gate's wound care and orthopedic implant coating opportunities.

TypeBroad incumbent
Description

Major biomaterials company offering coatings and materials for medical devices including antimicrobial solutions. Competes in the same antimicrobial surface coating space as Bio-Gate's HyProtect™ for implants.

TypeDirect peer
Description

German specialty chemicals company specializing in antiseptics, disinfectants, and antimicrobial technologies. Comparable to Bio-Gate's MicroSilver BG™ platform across consumer and medical applications.

TypeDirect peer
Description

Global medical products company with strong presence in advanced wound care and ostomy. Antimicrobial wound dressings overlap with Bio-Gate's MicroSilver BG™ wound care products.

TypeDirect peer
Description

Canadian antimicrobial testing company offering contract biofilm and antimicrobial testing services. Directly comparable to QualityLabs BT GmbH, Bio-Gate's accredited testing subsidiary.

TypeDirect peer
Description

Canadian antimicrobial coating company applying silver and other antimicrobial technologies to medical device surfaces and wound care products, directly comparable to Bio-Gate's HyProtect™ and MicroSilver BG™ platforms.

TypeBroad incumbent
Description

German trauma and orthopedic implant manufacturer. Comparable to Bio-Gate's medical technology segment and a potential customer for HyProtect™ coating of trauma implants, similar to the unnamed North American LOI partner.

TypeDirect peer
Description

US-based provider of surface modification coatings for medical devices. Although larger and more established, Surmodics competes in the same antimicrobial/functional coating space where Bio-Gate positions HyProtect™ for implant coatings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bio-Gate

Antimicrobial medical technologies and infection-prevention productsbio-gate.de

Bio-Gate AG is a German health technology company that develops silver-based antimicrobial technologies (MicroSilver BG™ additive and HyProtect™ plasma coating) for medical implants, wound care, derma cosmetics, veterinary, and industrial hygiene applications, and licenses them to medical device and consumer product partners globally.

What Bio-Gate does

Bio-Gate AG is a Nuremberg-based German health technology company founded in 2000, listed on the German stock exchange (ISIN DE000BGAG981), that develops and commercializes silver-based antimicrobial and antiviral technologies for use across medical, cosmetic, veterinary, and industrial applications. Its two proprietary platforms are MicroSilver BG™, a highly pure, microporous elemental silver additive that can be incorporated into materials and formulations, and HyProtect™, an ultrathin (<200 nm) plasma coating combining pure silver and polysiloxane designed to protect medical implant surfaces against bacterial colonization, including multi-resistant organisms. Manufacturing is conducted in Bremen under DIN EN ISO 13485:2016 and DIN EN ISO 9001:2015, and the MicroSilver BG ingredient carries ECOCERT, COSMOS, and NPA natural product certifications.

The company monetizes through three channels: (1) B2B technology licensing and coating services to medical device manufacturers (notably orthopedic and trauma implant partners, with an FDA-track trauma LOI and a CE-track hip revision RCT of 200+ patients expected to read out in 2027); (2) sale of proprietary consumer products spanning derma cosmetics, wound care, and animal care (including the Silver Honey® line with W.F. Young in North America and horse care SKUs); and (3) accredited microbiological laboratory services through its wholly owned subsidiary QualityLabs BT GmbH, whose CERTIKA methods are recognized by European notified bodies and stored as FDA master files. A veterinary-exclusive joint venture, VetInnovations GmbH, is co-owned with LABOKLIN.

Distribution is hybrid: direct enterprise field sales to global medical device companies combined with multi-channel retail and e-commerce distribution (PetSmart, Petco, Walmart, Tractor Supply, Amazon, Chewy) for animal care, plus pharmacy and drugstore channels for derma cosmetics. The company operates representative offices in Bolton, Ontario (RFH BioTek Inc.) and Guangzhou (WunderTek) to support North American and Chinese business development. FY2025 revenue was 7.4M EUR (+4.9% YoY), with the veterinary segment up 48% and EBITDA loss narrowing 31.3% to -896 TEUR as the company approaches operational break-even.

Bio-Gate firmographics

Firmographics
Name
Bio-Gate
Legal name
Bio-Gate AG
Website
https://bio-gate.de
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
Bio-Gate AG is a German health technology company that develops silver-based antimicrobial technologies (MicroSilver BG™ additive and HyProtect™ plasma coating) for medical implants, wound care, derma cosmetics, veterinary, and industrial hygiene applications, and licenses them to medical device and consumer product partners globally.
Ownership category
akta.pro rank

Bio-Gate industry classification

Industry
Product category
Antimicrobial medical technologies and infection-prevention products
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAMAEAE
Antimicrobials & Anti-infectives
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAGADAE
Microbiology & Sterility Assurance (Bioburden/Endotoxin/Sterility)
SECONDARYAFAJAFAF
Natural Antimicrobials & Clean-Label Preservatives (Plant Extracts, Essential Oils, Fermented Extracts)
Agriculture & Food Production/Food Ingredients & Additives/Preservatives & Antimicrobials (Organic Acids, Nitrates, Cultured Dextrose)

Keywords

  • Antimicrobial silver technology
  • Medical implant coatings
  • Antimicrobial wound care
  • Veterinary dermatology products
  • Industrial hygiene additives

Where Bio-Gate is headquartered

Location

Headquarters

HQ city
Nürnberg
HQ country
Germany
HQ region
Europe

Offices4 records

Markets served

Bio-Gate business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Technology Licensing and Coating Services: Licensing of proprietary antimicrobial technologies (MicroSilver BG™ and HyProtect™) to medical device manufacturers and consumer product companies. Revenue generated through technology licensing fees, development partnerships, and coating service contracts for implants and medical devices.
  2. Proprietary Consumer Products: Sale of finished derma cosmetics, wound care, and veterinary care products. Includes CBD-based skincare products, MicroSilver BG™ skincare lines, and animal care products distributed through retail chains, pharmacies, and veterinary channels.
  3. Laboratory Testing Services: Microbiological testing services through subsidiary QualityLabs BT GmbH, providing antimicrobial and anti-adhesive property testing using methods including CERTIKA, QualiScreen, ISO 22196/JIS Z 2801, ISO 20743/JIS L 1902, ASTM E 2180, ASTM E 2149.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

Bio-Gate product offering

Product offering

Core offering

Bio-Gate AG commercializes proprietary silver-based antimicrobial and antiviral technologies — MicroSilver BG™ (a microporous elemental silver additive) and HyProtect™ (an ultrathin plasma silver-polysiloxane coating) — applied to medical devices, wound care, derma cosmetics, veterinary products, and industrial materials. The company licenses its technologies to medical device manufacturers, coats implants and other products, sells branded consumer and animal care products, and offers accredited microbiological testing through its QualityLabs BT GmbH subsidiary.

Product overview

Bio-Gate AG is a health technology company specializing in antimicrobial and antiviral technologies. The core offerings consist of two proprietary technologies: MicroSilver BG™ (a highly pure elemental microporous silver additive) and HyProtect™ (an ultrathin plasma coating combining silver and polysiloxane). These technologies are applied across four main business segments: Medical Technology (wound dressings, implant coatings, dental materials, bone cement, catheters), Derma Cosmetics (skincare for acne, neurodermatitis, rosacea, diabetic foot), Veterinary (animal care products for skin/ear/wound care and implant coatings), and Industry+Hygiene (textiles, sprays, polymers, paints, foams). The company also operates QualityLabs BT GmbH for microbiological testing and VetInnovations GmbH as a joint venture for veterinary dermatology products.

Differentiator

Problem solved

Functional benefit

Brands

  • HyProtect: Ultrathin plasma coating technology that protects medical implant surfaces against bacterial colonisation using polysiloxane and silver combination.
  • MicroSilver BG
  • Silver Honey Rapid Ear Care

Products and services

  • MicroSilver BG™ MicroSilver BG™ is a highly pure, microporous elemental silver additive with antimicrobial and antiviral properties. It is supplied as an ingredient or additive that can be incorporated into materials and formulations for skincare, oral care, wound care, textiles, polymers, paints, foams, and medical implants. Certified natural by ECOCERT, COSMOS, and NPA.
  • HyProtect™ Coating Technology
  • HyProtect™-coated Implants
  • Wound Dressings with MicroSilver BG™
  • Dental Materials with MicroSilver BG™
  • Bone Cement with MicroSilver BG™
  • Derma Cosmetic Products with MicroSilver BG™
  • CBD Muscle Gel
  • Silver Honey® Rapid Ear Care Line
  • Veterinary Skin, Ear, and Wound Care Products
  • Horse Care Products (Balm, Spray, Strahlgel)
  • MicroSilver BG™-Tec Industrial Additives (Textiles, Polymers, Paints, PU Foams, Sprays)
  • QualityLabs BT GmbH Accredited Microbiological Testing Services
  • VetInnovations GmbH Veterinary Dermatology Products

Quantifiable outcome

  • Infection rate <1% with HyProtect™ coated veterinary implants vs typical 15% infection rate
  • +5 more outcomes

Companies that use Bio-Gate

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles5 records

Bio-Gate technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Bio-Gate partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered major, core and minor.

  • North American Medical Device Manufacturer (Trauma)majorStrategic or Co-development Partner · 31 July 2023Letter of Intent signed for use of Bio-Gate's HyProtect™ coating process for trauma implants following FDA approval. Represents significant growth potential in human medicine market.
  • W. F. YoungcoreChannel Partner/ Reseller/ Distributor · 1 February 2023US-based animal health specialist distributing Silver Honey® Rapid Ear Care line products developed and manufactured by Bio-Gate. Products combine MicroSilver BG™ and Manuka honey for antibiotic-free ear infection treatment in pets.
  • Dermatest GmbHminorStrategic or Co-development Partner · 1 January 2023Independent dermatological testing institute in Münster conducting clinical studies on Bio-Gate products. Awarded 'sehr gut' (very good) rating to CBD muscle gel in 2025 study.
  • QualityLabs BT GmbHcoreOthers · 1 January 2004Accredited microbiological testing laboratory spun off from Bio-Gate in 2004. Provides antimicrobial testing services including CERTIKA test methods recognized by European notified bodies and FDA. Generates testing services revenue for the group.
  • VetInnovations GmbHcoreStrategic or Co-development PartnerJoint venture between LABOKLIN GmbH & Co. KG and Bio-Gate AG developing and selling dermatological care and wound care products for small animals. Products based on MicroSilver BG™ technology. Exclusively serves veterinarians.
  • LABOKLIN GmbH & Co. KGcoreStrategic or Co-development PartnerVeterinary laboratory and diagnostics company co-founding VetInnovations joint venture with Bio-Gate for veterinary dermatology products.
  • RFH BioTek Inc.majorChannel Partner/ Reseller/ DistributorNorth American representative office in Bolton, Ontario representing Bio-Gate for veterinary products and business development. Contact: Karl F. Richter.
  • Guangzhou WunderTek Biotechnology Co. LtdminorChannel Partner/ Reseller/ DistributorChinese representative office in Guangzhou providing local business development and customer support for Chinese market.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Bio-Gate competitors and assessment

Company assessment

Broad incumbents

  • B. Braun: Large German medical device and pharmaceutical company with broad portfolio including antiseptics, wound care, and orthopedic implants. Overlaps with Bio-Gate's medical technology segment as a broader incumbent competitor and potential customer for HyProtect™ coating.
  • Smith & Nephew: Global medical technology company with wound care, orthopedics, and sports medicine franchises. Comparable across both Bio-Gate's wound care and orthopedic implant coating opportunities.
  • DSM Biomedical: Major biomaterials company offering coatings and materials for medical devices including antimicrobial solutions. Competes in the same antimicrobial surface coating space as Bio-Gate's HyProtect™ for implants.
  • aap Implantate: German trauma and orthopedic implant manufacturer. Comparable to Bio-Gate's medical technology segment and a potential customer for HyProtect™ coating of trauma implants, similar to the unnamed North American LOI partner.

Direct peers

  • Mölnlycke Health Care: Global wound care specialist (Mepilex, etc.) with antimicrobial dressings. Comparable to Bio-Gate's wound care segment using MicroSilver BG™ in wound dressings, though at much larger scale.
  • Schülke & Mayr: German specialty chemicals company specializing in antiseptics, disinfectants, and antimicrobial technologies. Comparable to Bio-Gate's MicroSilver BG™ platform across consumer and medical applications.
  • ConvaTec: Global medical products company with strong presence in advanced wound care and ostomy. Antimicrobial wound dressings overlap with Bio-Gate's MicroSilver BG™ wound care products.
  • Innovotech: Canadian antimicrobial testing company offering contract biofilm and antimicrobial testing services. Directly comparable to QualityLabs BT GmbH, Bio-Gate's accredited testing subsidiary.
  • Covalon Technologies: Canadian antimicrobial coating company applying silver and other antimicrobial technologies to medical device surfaces and wound care products, directly comparable to Bio-Gate's HyProtect™ and MicroSilver BG™ platforms.
  • Surmodics: US-based provider of surface modification coatings for medical devices. Although larger and more established, Surmodics competes in the same antimicrobial/functional coating space where Bio-Gate positions HyProtect™ for implant coatings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Bio-Gate compliance and trust

Trust signal

Compliance5 records

Bio-Gate financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bio-Gate leadership team

Management profile

Number of profiles

Profiles7 records

Bio-Gate subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Bio-Gate funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bio-Gate M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio-Gate

What does Bio-Gate do?

Bio-Gate AG commercializes proprietary silver-based antimicrobial and antiviral technologies — MicroSilver BG™ (a microporous elemental silver additive) and HyProtect™ (an ultrathin plasma silver-polysiloxane coating) — applied to medical devices, wound care, derma cosmetics, veterinary products, and industrial materials. The company licenses its technologies to medical device manufacturers, coats implants and other products, sells branded consumer and animal care products, and offers accredited microbiological testing through its QualityLabs BT GmbH subsidiary.

Is Bio-Gate a public or private company?

Bio-Gate is a public company. It is classified as public and is currently operating.

When was Bio-Gate founded?

Bio-Gate was founded in 2000. It employs 11 to 50 people.

Where is Bio-Gate based?

Bio-Gate is headquartered in Nürnberg, Germany, in the Europe region.

How does Bio-Gate make money?

Three revenue lines are on record. Technology Licensing and Coating Services are the primary driver. The others are proprietary Consumer Products and laboratory Testing Services.

Who are Bio-Gate's main competitors?

Broad incumbents on record are B. Braun, Smith & Nephew, DSM Biomedical and aap Implantate. Direct peers are Mölnlycke Health Care, Schülke & Mayr, ConvaTec, Innovotech, Covalon Technologies and Surmodics.

Does Bio-Gate have an API?

No public API is recorded for Bio-Gate.

What industry is Bio-Gate in?

Bio-Gate's product category is Antimicrobial medical technologies and infection-prevention products. Its primary akta.pro industry code is HLAMAEAE, Antimicrobials & Anti-infectives, with a secondary code of HLAGADAE, Microbiology & Sterility Assurance (Bioburden/Endotoxin/Sterility). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StAnalysts Expect Breakeven For Bio-Gate AG (FRA:BIG) Before LongAnalysts expect Bio-Gate AG to breakeven in 2028, after a final loss in 2027, requiring an average annual growth rate of 74%. The company has no debt, operating off shareholder funding, which reduces repayment risk.FinanzNachrichten.deEQS-News: Bio-Gate AG veröffentlicht Halbjahresergebnis 2026Bio-Gate AG reported H1 2026 revenue of €2.8 million, down 18% year-over-year, with an EBIT loss of €927,000. The board expects revenue to recover in 2027 and adjusted its full-year 2026 forecast to €6.0–6.9 million, with EBITDA loss of €0.9–1.1 million.FinanzNachrichten.deBio-Gate senkt Prognosen nach schwächeren KundenabrufenBio-Gate AG cut its 2026 revenue forecast after two large customers in human and animal care reduced their order volumes. The reductions stem from changes in their product portfolios and organizational changes, affecting the company's derma-cosmetics segment.FinanzNachrichten.deEQS-Adhoc: Bio-Gate AG passt Umsatz- und Ergebnisprognose für das Geschäftsjahr 2026 anBio-Gate AG revised its 2026 revenue and EBITDA forecasts, citing two major customers reducing orders in its derma-cosmetics and wound-care segments. The company now expects revenue of €6.0–6.9 million and EBITDA of -€0.9 to -€1.1 million, down from previous estimates. It anticipates recovery in 2027 with a new scar-treatment product and a new product line for the animal-care customer.FinanzNachrichten.deOriginal-Research: Bio-Gate AG (von BankM AG): KaufenBankM AG has initiated coverage on Bio-Gate AG, a Nuremberg-based health technology company specializing in silver-based surface technology for medical devices, with a "Buy" rating and a 12-month price target corridor of €6.78–8.30. The recommendation is based on Bio-Gate's proprietary HyProtect plasma coating technology for antimicrobial implant surfaces and its MicroSilverBG product line serving cosmetics, wound care, veterinary, and industrial applications. The analyst firm cites the company's long-term collaborations with leading medical device manufacturers and regulatory certifications as substantial market entry barriers.FinanzNachrichten.deBio-Gate mit Kapitalerhöhungen und einer Aktien-ZusammenlegungBio-Gate AG's management board, with supervisory board approval, has decided on a capital increase from authorized capital, issuing up to 407,747 new shares at a price of 2.80 euros per share. The shares will be placed through a private placement with the legal subscription rights of existing shareholders excluded.FinanzNachrichten.deEQS-Adhoc: Bio-Gate AG beschließt Kapitalerhöhung aus genehmigtem Kapital und gibt Bedingungen der von der Hauptversammlung am 30. Juni 2026 beschlossenen Bezugsrechtsemission bekanntBio-Gate AG's management board has decided to increase the company's share capital by up to €407,747 through the issuance of new shares at €2.80 per share via private placement, raising approximately €1.14 million in gross proceeds. The capital increase aims to strengthen the company's financial flexibility and enable execution of its planned growth strategy. Additionally, the board has set terms for a rights issue also approved by shareholders on June 30, 2026, with a subscription period from July 30 to August 13, 2026.FinanzNachrichten.deOriginal-Research: Bio-Gate AG (von GBC AG): KaufenGBC AG published a research report on Bio-Gate AG maintaining a 'Buy' rating with a price target of €3.40 as of year-end 2027. The German antimicrobial technology company reported 2025 revenue growth of 4.9% to €7.40 million and improved EBITDA to -€0.90 million from -€1.30 million year-on-year, driven by higher value-added production at its Bremen facility and cost reduction measures. Bio-Gate's veterinary business showed particularly strong international growth in North America, while the strategically important medical technology segment with its HyProtect implant coating continues to advance with ongoing projects targeting commercial scaling from 2028-2029, supported by a recently approved 5:1 share consolidation and accompanying capital increase to strengthen the balance sheet.Business & FinancialBio-Gate Strengthens Its Presence In North America With Increased Sales Of Animal Care Products To Veterinarians And Pet OwnersBio-Gate AG launched new animal care products at the North American Veterinary Dermatology Forum in Orlando, expanding its North American presence. The company expects a multiplier effect from the launch, with North American animal care sales projected to reach $88.3 billion in 2024 and $152.2 billion by 2033.FmiblogAntimicrobial Nano-coatings: A Sustainable Solution for Enhanced Hygiene in Healthcare and BeyondThe antimicrobial nano-coatings market is projected to grow at a 20.3% CAGR from 2022 to 2032, reaching over USD 5,893.7 million. Demand is driven by healthcare, food, and packaging sectors, with key players including Bio-Gate AG and Nano-Care Deutschland AG.